Skip to main content
. 2017 Sep 5;6:e24196. doi: 10.7554/eLife.24196

Figure 1. Sequencing flow chart for samples obtained in CYD-TDV trials.

(A) CYD14, (B) CYD15.

Figure 1—source data 1. Sequence alignment of DENV-1 prM and E genes from CYD-TDV trials.
elife-24196-fig1-data1.fasta (497.5KB, fasta)
DOI: 10.7554/eLife.24196.005
Figure 1—source data 2. Sequence alignment of DENV-2 prM and E genes from CYD-TDV trials.
elife-24196-fig1-data2.fasta (377.5KB, fasta)
DOI: 10.7554/eLife.24196.006
Figure 1—source data 3. Sequence alignment of DENV-3 prM and E genes from CYD-TDV trials.
elife-24196-fig1-data3.fasta (211.7KB, fasta)
DOI: 10.7554/eLife.24196.007
Figure 1—source data 4. Sequence alignment of DENV-4 prM and E genes from CYD-TDV trials.
elife-24196-fig1-data4.fasta (220.2KB, fasta)
DOI: 10.7554/eLife.24196.008

Figure 1.

Figure 1—figure supplement 1. Probability of sequencing success versus viremia.

Figure 1—figure supplement 1.

White boxes show the range and IQR of viremia levels from successful sequencing attempts, grey boxes show the range and IQR of viremia levels from unsuccessful sequencing attempts. (A) DENV-1, (B) DENV-2, (C) DENV-3, (D) DENV-4.